Can Fite BioPharma Ltd (CANF)

[midastouch017]

US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

https://finance.yahoo.com/news/us-patent-office-granted-fite-120000820.html

The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile

Ramat Gan, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US patent office. Namodenoson is currently being developed for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), advanced liver cancer and pancreatic cancer. In all clinical studies that have been conducted, Namodenoson had a very favorable safety profile when administered orally.

The patent application No. 17/309,952 entitled “An A3 adenosine receptor ligand for use for achieving a fat loss effect”, has been accepted by the US Patent Office, will be issued on February 2nd and expires in 2042.

The patent application covers methods of treating obese patients by administering Namodenoson in an oral formulation. Can-Fite has already multiple approved patents and corresponding applications in a variety of territories around the world, for different clinical applications of the drug.

The anti-obesity patent application is based on data demonstrating that treatment of fat cells with Namodenoson reduced fat levels via the increase of the hormone adiponectin, a regulator of fat production in the body. Namodenoson also reduced body weight in an experimental animal model of obesity, induced by high fat diet. In a MASH Phase IIa study, in patients treated with Namodenoson, a 2.3% weight loss has been observed after 3 months with a significant increase in serum adiponectin levels.

”We are delighted that the product protection of Namodenoson in the area of obesity has been accepted in the US and will be valid till 2042. Namodenoson is currently being developed for the treatment of MASH in a Phase IIb study where most patients are obese. We look forward to seeing the anti-obesity effect in this clinical study”, said Motti Farbstein, Can-Fite CE&CFO.

The obesity treatment industry worldwide is expected to reach a projected revenue of US$ 60.5 billion by 2030. A compound annual growth rate of 22.3% is expected of the worldwide obesity treatment industry from 2025 2030.